CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Biologic Therapies for Rheumatoid Arthritis: Navigating the Changing Treatment Paradigm CME
Faculty: Marc D. Cohen, MD; David A. Fox, MD
Disclosures

Release Date: August 30, 2002; Valid for credit through August 30, 2003

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Biologic Therapies for Rheumatoid Arthritis: Navigating the Changing Treatment Paradigm" symposium, which was held on February 2, 2002 in Chicago, Illinois.

Contents of This CME Activity
  1. The Biology of Inflammation: Immunology and Rheumatoid Arthritis
    Heterogeneity of Cell Types in the Rheumatoid Synovium
    Cytokines in Chronic Inflammation
    Cytokines in the Rheumatoid Synovium
    Tumor Necrosis Factor in Rheumatoid Arthritis
    Tumor Necrosis Factor Receptors
    Interleukin-1 Biology
    Interleukin-1 in Rheumatoid Arthritis
    Current Biologic Agents and Future Targets for Rheumatoid Arthritis Therapy

  2. How Biologic Agents Are Revolutionizing the Treatment of Rheumatoid Arthritis
    A Summary of Rheumatoid Arthritis Therapy
    Etanercept Monotherapy Trial
    Etanercept Monotherapy Trial: Open-Label Extension
    Results From the Etanercept Monotherapy Trial Open-Label Extension
    Etanercept Monotherapy vs Methotrexate in Early Rheumatoid Arthritis
    Results From Etanercept Monotherapy vs Methotrexate in Early Rheumatoid Arthritis
    Monotherapy With Infliximab
    Tapering Concomitant Therapy While on Infliximab
    Anakinra Monotherapy
    Combination Therapy With Etanercept and Methotrexate
    Combination Therapy With Infliximab and Methotrexate
    Combination Therapy With Anakinra and Methotrexate
    Etanercept Safety Experience
    Infliximab Safety Experience
    Anakinra Safety Experience
    Conclusions

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, the CME provider, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity

 
Copyright © 2002 Discovery International
Amgen, Wyeth
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.